{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T13:49:27Z","timestamp":1722260967214},"reference-count":5,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.vaccine.2006.11.040","type":"journal-article","created":{"date-parts":[[2006,12,5]],"date-time":"2006-12-05T12:11:14Z","timestamp":1165320674000},"page":"2766-2767","source":"Crossref","is-referenced-by-count":5,"title":["Gorse GJ, et al. \u201cImmunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial\u201d [Vaccine 24 (2006) 5950\u20135959]"],"prefix":"10.1016","volume":"25","author":[{"given":"Thomas K.","family":"Zink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"33\u201334","key":"10.1016\/j.vaccine.2006.11.040_bib1","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rpa102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.040_bib2","unstructured":"DHHS-FDA. 51058. Federal register, vol. 50, no. 240. Friday, December 13, 1985. Part II. In FDA, 1985."},{"key":"10.1016\/j.vaccine.2006.11.040_bib3","unstructured":"DHHS-FDA. Biological products; bacterial vaccines and toxoids; implementation of efficacy review; anthrax vaccine adsorbed; FINal order, federal register 2005; 70:75180-198 (December 19, 2005). (\u201cFinal Order\u201d)."},{"issue":"12","key":"10.1016\/j.vaccine.2006.11.040_bib4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/pds.936","article-title":"Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the vaccine adverse event reporting system (VAERS)","volume":"13","author":"Sever","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2006.11.040_bib5","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0264-410X(01)00462-5","article-title":"Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06012497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06012497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T01:57:29Z","timestamp":1547171849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06012497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":5,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0264410X06012497"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.11.040","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}